- Home
- CMP vs CELC Comparison
CMP vs CELC Comparison
Compare CMP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMP
- CELC
- Stock Information
- Founded
- CMP 1993
- CELC 2011
- Country
- CMP United States
- CELC United States
- Employees
- CMP N/A
- CELC N/A
- Industry
- CMP Other Metals and Minerals
- CELC Medical Specialities
- Sector
- CMP Basic Materials
- CELC Health Care
- Exchange
- CMP Nasdaq
- CELC Nasdaq
- Market Cap
- CMP 493.5M
- CELC 440.7M
- IPO Year
- CMP 2003
- CELC 2017
- Fundamental
- Price
- CMP $12.05
- CELC $13.15
- Analyst Decision
- CMP Buy
- CELC Strong Buy
- Analyst Count
- CMP 3
- CELC 6
- Target Price
- CMP $18.33
- CELC $30.17
- AVG Volume (30 Days)
- CMP 614.2K
- CELC 175.7K
- Earning Date
- CMP 02-10-2025
- CELC 03-26-2025
- Dividend Yield
- CMP 1.28%
- CELC N/A
- EPS Growth
- CMP N/A
- CELC N/A
- EPS
- CMP N/A
- CELC N/A
- Revenue
- CMP $1,082,900,000.00
- CELC N/A
- Revenue This Year
- CMP $4.71
- CELC N/A
- Revenue Next Year
- CMP $7.26
- CELC N/A
- P/E Ratio
- CMP N/A
- CELC N/A
- Revenue Growth
- CMP N/A
- CELC N/A
- 52 Week Low
- CMP $7.51
- CELC $10.35
- 52 Week High
- CMP $23.59
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- CMP 50.04
- CELC 60.85
- Support Level
- CMP $10.54
- CELC $12.55
- Resistance Level
- CMP $12.17
- CELC $13.25
- Average True Range (ATR)
- CMP 0.83
- CELC 0.68
- MACD
- CMP 0.03
- CELC 0.14
- Stochastic Oscillator
- CMP 68.02
- CELC 85.79
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.